Published in final edited form as:

Chemistry. 2014 June 2; 20(23): 6861–6865. doi:10.1002/chem.201402573.

A Versatile Bioorthogonal Copper-free Click Chemistry Platform to Functionalize Cisplatin Prodrugs

Rakesh K. Pathak^[a], Christopher D. McNitt^[b], Vladimir V. Popik^[b], and Shanta Dhar^{[a],*}

^[a]NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602.

^[b]Department of Chemistry, University of Georgia, Athens, GA 30602.

Abstract

The ability to rationally design and construct a platform technology to develop new platinum(IV) [Pt(IV)] prodrugs with functionalities for installation of targeting moieties, delivery systems, fluorescent reporters from a single precursor with the ability to release biologically active cisplatin using well-defined chemistry is critical for discovering new platinum-based therapeutics. With limited numbers of possibilities by considering the sensitivity of Pt(IV) centers to reduction, thiols, etc, we used a strain promoted azide alkyne cycloaddition (SPAAC) approach to provide a novel platform where new functionalities can easily be installed on cisplatin prodrugs from a single Pt(IV) precursor. The ability of this platform to be incorporated in nano-delivery vehicle and conjugation to fluorescent reporters were also investigated.

Keywords

Click chemistry; Cisplatin; Prodrug; Nanoparticle

The discovery of *cis*-diamminedichlorido-platinum(II) or cisplatin^[1] and its huge success in the treatment of a variety of tumors led the exploration of new platinum compounds. The need for new platinum complexes with remarkable anticancer properties and selectivity to reduce side effects and overcome resistance shown by cisplatin demand the ability to install targeting moieties, delivery systems, and a second therapeutic on the platinum center.^[2] The biological activity of cisplatin begins with aquation inside cell with the loss of one or both chloride ligands to generate highly electrophilic platinum(II) aqua complexes which readily react with biological nucleophiles including the N7 position of purine DNA bases resulting intra and interstrand cross-links with nuclear DNA.^[3] This series of biological activities imposes limitation on the strategies to synthesize new Pt(II) complexes. The non-leaving group ligands which stay bound to the Pt(II) center upon DNA binding offer only limited modifications without affecting the biological activity.^[2] The requirement of good leaving group for aquation introduces further limitation to incorporate new functionalities on the Pt(II) centers.

*Fax: (+) 706-542-9454, shanta@uga.edu, Homepage: <http://shanta.chem.uga.edu>.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/chem.201402573>.

The kinetically ‘inert’ Pt(IV) prodrugs with two available axial sites can be an attractive way to introduce new functionalities on platinum. Pt(IV) compounds show biological activities which involve reduction to Pt(II) prior to DNA binding.^[4] The ability to rationally design and construct a platform technology to develop new platinum(IV) prodrugs using well-defined synthetic chemistry from a single precursor can be of enormous benefit for discovering new therapeutics. Anhydrides are widely used as electrophiles for installation of new functionalities on relatively weak nucleophilic Pt(IV)-OH.^[5] However, all anhydrides are not stable and a large number of molecules of interest lack acid functionality for transformation to anhydrides. Click chemistry can be a convenient way to introduce multiple ligands.^[6] However, possibility of Pt(IV) reduction by Cu(I) catalyst of the copper-catalyzed azide-alkyne cycloaddition (CuAAC) and cytotoxicity of remaining copper are limiting factors for utility of CuAAC-click reactions for synthesis of new multifunctional Pt(IV) prodrugs. Thus, only a limited number of examples documented CuAAC-click reaction on Pt(IV) compounds with poor yields.^[7] With such issues in mind, we describe a platform technology by using Cu(I) free strain-promoted cycloaddition approach,^[8] a single Pt(IV) precursor Platin-Az, and functionalized azadibenzocyclooctyne (ADIBO) derivatives for easy installation of new functionalities on Pt(IV) centers in a single step (Figure 1).

ADIBO-based cycloaddition probes are excellent for introducing new functionalities and to increase lipophilic properties of molecules of interest for their biological activities.^[9] A new terminal azide appended Pt(IV) compound, Platin-Az was synthesized (Scheme 1, Figures S1-S6) as a precursor which can be used in a variety of SPAAC reaction with functionalized ADIBO-X derivatives (Figure 1). To demonstrate the effectiveness of this platform, an acid functionalized ADIBO-COOH was synthesized by reacting ADIBO-NH₂ with succinic anhydride (Scheme 1, Figures S7, S8). Reaction of Platin-Az with ADIBO-COOH resulted in Platin-CLK in a single step in an efficient manner (Scheme 1, Figures S9-S13). The success in performing SPAAC reaction on Pt(IV) prodrug indicated that this technology in conjunction with Platin-Az can be used to introduce numerous functionalities when one uses suitably functionalized ADIBO derivatives for incorporation of another therapeutic, targeting moiety, fluorescent reporter, drug delivery system etc. A comparison of redox potentials of Platin-Az and Platin-CLK at two different pH values of 6.0 and 7.4 demonstrated that introduction of ADIBO functionality does not change the redox behavior of the prodrug; favorable redox parameters required for cellular reduction of Platin-CLK to cisplatin were noted (Figure S14). DNA binding ability of cisplatin produced upon reduction of Platin-CLK with sodium ascorbate followed by reaction with 2'-deoxyguanosine 5'-monophosphate sodium salt hydrate (5'-dGMP) as a truncated version of DNA was investigated. Product analysis by matrix-assisted laser desorption/ionization (MALDI)-time of flight (TOF)-mass spectrometry (MS) analysis confirmed formation of Pt^{II}-5'-dGMP-bisadduct, [Pt(NH₃)₂(5'-dGMP-N7)₂] (m/z = 922, Figure S15) suggesting that cisplatin released upon reduction of Platin-CLK forms the desired DNA adduct.

The anti-proliferative properties of the newly synthesized Pt(IV) complexes, Platin-Az and Platin-CLK were tested in prostate cancer (PCa) PC3 and DU145 cell lines. Cisplatin and ADIBO-COOH were used as controls. Incubation of PC3 and DU145 cells with different concentrations of Platin-Az and Platin-CLK for 72 h followed by cell survival analyses using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay

demonstrated that these complexes show efficient cell killing behavior (Figure 2A, Table S1, Figure S16). The relative non-toxic behavior of ADIBO-COOH indicated that functionalized ADIBO-based derivatives could be used to introduce variety of functionalities on platinum center. Platin-Az, the precursor for SPAAC was found to be more efficient in killing PCa cells and its activity was better than cisplatin and Platin-CLK. We believe that this enhanced activity is due to the presence of terminal azide groups. This is supported by the fact that *cis,cis,trans*-[Pt(NH₃)₂Cl₂{OOC(CH₂)₂CH₃}₂] or butyroplatin, a Pt(IV) compound devoid of such terminal azide group showed less cytotoxicity in these cells (Table S1, Figure S16). Butyroplatin was synthesized following a modified literature reported method (Figure S17-S19).^[10] We would like to stress that an enhanced toxicity of Platin-Az will not be a problem since the SPAAC will be carried out *in vitro* for installing other moieties on to Pt(IV). Comparable cytotoxicity of the clicked product, Platin-CLK and butyroplatin indicated that installation of ADIBO did not cause any additional toxicity, thus the SPAAC approach will serve as a versatile platform to install other biomolecules effectively on to Pt(IV) prodrugs.

The ability to install a robust near-infrared fluorescent reporter such as Cy5.5 on Platin-Az using SPAAC was investigated. A Cy5.5-functionalized ADIBO derivative, ADIBO-Cy5.5, was used to construct Platin-Cy5.5 from Platin-Az (Figure 2A, Figures S20 and S21). Live cell imaging of Platin-Cy5.5 treated PC3 cells provided insight into the cellular uptake properties of this series of Pt(IV) prodrugs (Figure 2B). Confocal microscopy analysis of the treated cells indicated significant cellular internalization of this prodrug. Construction of Platin-Cy5.5 from Platin-Az and ADIBO-Cy5.5 using SPAAC and its cellular uptake by imaging studies demonstrated the ability to install a fluorescent reporter in this platform for possible use in theranostics. The fluorescence quenching of fluorophores upon coordination to heavy platinum center^[11] is often viewed as a problem to understand biodistribution (bioD) and biotransformation of such compounds. Since fluorescence quenching by Pt through the heavy-atom effect depends on the spatial separation between the fluorophore and the metal center, the ability of ADIBO-based ligand to install the fluorophore at a long distance from the Pt center will be an additional feature of the current platform for possible uses in theranostics.

Clinical translation of small molecule-based therapies face tremendous challenges due to their poor bioD and pharmacokinetic (PK) properties, rapid clearance, and marked toxicity. Nanoparticles (NPs) due to their large size compared to small molecules, hold promise as carriers.^[12] Inclusion of platinum-based compounds into NP delivery vehicles have obvious benefits which include better selectivity and lesser side effects.^[13] Controlled release polymers have tremendous potential for fabrication of drug-encapsulated NPs.^[14] The plethora of NP platforms available, in addition to the various methods in hand to combine them with drugs, allows researchers to fine-tune the pharmacological profile of the drugs *ad infinitum*. Polymeric NPs of poly(lactide-*co*-glycolide)-*b*-polyethyleneglycol (PLGA-*b*-PEG) block copolymer are especially promising as drug delivery vehicles.^[15] The use of PLGA and PEG polymers in the Food and Drug Administration (FDA) approved products makes these biomaterials ideal for development of therapeutic NPs. PLGA-*b*-PEG-NPs with the advantages of controlled release, long shelf life, extended blood circulation half-life, ability

to carry a large drug payload, and high therapeutic index are now in clinical trials.^[16] PLGA-*b*-PEG-NPs can be used as delivery vehicles for Pt(IV)-based compounds.^[15c, 17] However, successful engineering of polymeric NPs loaded with Pt(IV) compounds depends on the hydrophilicity/hydrophobicity of the molecule of interest. Most Pt(IV) compounds show very low loadings without compromising suitable NP sizes required for tumor accumulation.^[10, 17a, 17b] We investigated the ability of Platin-CLK-based prodrugs to be encapsulated in PLGA-*b*-PEG-based NPs. The interior of PLGA-*b*-PEG-NPs is more hydrophobic than their surface and the presence of hydrophobic moieties on ADIBO increased the lipophilic character of Platin-CLK making it convenient for NP-based delivery approaches to manage PK and bioD properties of such Pt complexes. PLGA-COOH and OH-PEG-OH polymers were used to prepare PLGA-*b*-PEG-OH copolymer (Figures S22-S24).^[18] We used a nanoprecipitation method^[18] to encapsulate Platin-CLK and the NPs were characterized by dynamic light scattering (DLS) to give the size, polydispersity, and zeta potential of each preparation (Figure 3, Table S2, Figure S25). Morphology of these NPs was checked using transmission electron microscopy (TEM) (Figure 3). The loading and encapsulation efficiency (EE) of Platin-CLK at various added weight-percentage values of Pt(IV) to polymer are shown in Figure 3. In comparison, our effort to encapsulate the precursor Platin-Az lacking the hydrophobic ADIBO moieties in PLGA-*b*-PEG-NPs under the same conditions resulted significantly lower loading and EE (Figure 3, Figure S26, and Table S3). The ability to load Platin-CLK inside PLGA-*b*-PEG-NPs without compromising the size of the NPs further demonstrated the usefulness of this platform to be incorporated in a nano-formulation (Figure 3). The octahedral platinum(IV) prodrugs are generally substitution-inert.^[19] However, the incorporation of kinetically “inert” Pt(IV) prodrugs into delivery vehicles produce formulations which often lacks enough long-term stability for making a practical drug.^[13, 20] Our current approach of making a prodrug with such easiness and their rapid modular assembly using polymeric NPs prior to administration can be beneficial for clinical translation.

In this communication, we developed a platform technology for construction of Pt(IV) complexes containing functionalities such as cell receptor targeting moiety, a delivery system, other therapeutics, or fluorescent reporters with easiness and high efficacy. A versatile Pt(IV) prodrug Platin-Az was synthesized to use as an universal precursor in SPAAC reaction. Using this precursor, we demonstrated the utility of SPAAC reaction in presence of ADIBO-X to introduce new functionalities with easiness and high efficacy. We demonstrated the ability of these complexes to be entrapped in the hydrophobic core of PLGA-*b*-PEG-based NPs. Unique ability of this platform for easy installation of a fluorescent cell reporter such as Cy5.5 was performed for tracking Pt(IV) prodrugs in live cells. These new Pt(IV) compounds demonstrated favorable redox and anti-proliferative properties. The modular designing of this platform and the huge scope to introduce multiple functionalities with high efficiency using well-defined synthetic chemistry make this work a key platform for discovering new platinum-based therapeutic agents.

Experimental Section

Details of materials and instrumentation, synthetic methods, additional experimental details and data. are available in Supporting Information.

Synthesis of Platin-Az

A mixture of *c,c,t* [PtCl₂(NH₃)₂(OH)₂] (0.54 g, 1.60 mmol) and 6-azidohexanoic anhydride (1.7 g, 5.6 mmol) in DMSO (5 mL) was stirred for 24 h. The solvent was then removed by multiple diethyl ether wash. The crude product was purified by dissolving in acetonitrile and precipitated with diethyl ether to get a light yellow solid. Yield 0.63 g (64%). ¹H NMR (400 MHz, CDCl₃): δ 6.50 (m, 6H), 3.27 (t, 4H), 2.19 (t, 4H), 1.28-1.45 (m, 12H) ppm (Figure S5). ¹³C NMR (100 MHz, CDCl₃): δ 181.13, 51.02, 35.92, 28.43, 26.15, 25.37 ppm (Figure S6). ¹⁹⁵Pt (DMSO-d₆, 107.6 MHz) (Figure S7): δ ppm 1215.33. HRMS m/z Calcd. for C₁₂H₂₇Cl₂N₈O₄Pt: (M+H)⁺ 612.1180. Found 612.1159 (Figure S8). Elemental analysis calcd (%) for C₁₂H₂₆Cl₂N₈O₄Pt: C 23.54, H 4.28, N 18.30; found: C 23.36, H 4.57, N 18.75.

Synthesis of Platin-CLK

A solution of Platin-Az (80 mg, 0.13 mmol) and ADIBO-COOH (103 mg, 0.27 mmol) in 5 mL of dry dimethylformamide (DMF) was stirred at room temperature for 12 h. The solvent was evaporated under reduced pressure. *Note:* The temperature during rotavap should be kept below 40 °C. The crude product was suspended in CH₂Cl₂ and acetonitrile (1:2) and precipitated with diethyl ether (6x). Finally the product was isolated by precipitating with CH₂Cl₂:diethyl ether (2:8) to get an off white solid. Yield, 141 mg, 79%. ¹H NMR (DMSO-d₆, 400 MHz): δ 12.02 (broad s, 2H), 7.26-7.72 (m, 18H), 6.53 (broad, 6H), 5.84-5.97 (m, 2H), 4.35-4.46 (m, 4H), 4.22 (m, 2H), 2.98 (t, 4H), 2.87 (m, 2H), 2.33 (t, 4H), 2.19 (m, 8H), 1.82-1.94 (m, 4H), 1.35-1.64 (m, 10H), 1.01-1.10 (m, 2H) ppm (Figure S9). gradient-selected COSY (Figure S10). ¹³C NMR (DMSO-d₆, 100 MHz): δ 181.17, 181.14, 181.12, 174.31, 174.29, 171.40, 171.24, 170.17, 169.76, 144.18, 143.27, 142.63, 141.37, 140.47, 135.81, 134.27, 134.20, 132.68, 132.38, 132.02, 131.17, 130.27, 130.20, 129.96, 129.71, 129.60, 129.12, 128.79, 128.74, 127.91, 127.32, 127.29, 124.71, 52.27, 50.93, 48.90, 48.17, 35.91, 35.70, 35.23, 35.19, 33.84, 33.78, 30.29, 30.25, 29.67, 29.52, 29.49, 29.46, 26.27, 25.55, 25.36, 25.19 ppm (Figure S11). *Note: ADIBO triazole is known to exhibit different isomers and this phenomenon is reflected in the ¹³C NMR peaks.* ¹⁹⁵Pt (DMSO-d₆, 107.6 MHz): δ 1213.97 ppm (Figure S12). HRMS m/z Calcd. for C₅₆H₆₇Cl₂N₁₂O₁₂Pt: (M+H)⁺ 1364.4026. Found 1364.4027 (Figure S13). Elemental analysis calcd (%) for C₅₆H₆₆Cl₂N₁₂O₁₂Pt.CH₃CN.CH₂Cl₂: C 47.52, H 4.80, N 12.21; found: C 47.10, H 5.09, N 12.24.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank Dr. Ramaraja Ramasamy for potentiostat. We thank Sean Marrache for assistance with confocal microscopy. This work was supported by a startup fund from the Office of the Vice President for Research, University of Georgia (UGA) to S.D., Department of Defense Prostate Cancer Idea award (W81XWH-12-1-0406) to S.D., and by a grant from the National Institutes of Health (R01CA157766) to V.V.P.

References

- [1]a). Rosenberg B, VanCamp L, Trosko JE, Mansour VH. *Nature*. 1969; 222:385–386. [PubMed: 5782119] b) Wang D, Lippard SJ. *Nat Rev Drug Discov*. 2005; 4:307–320. [PubMed: 15789122]
- [2]. Wilson JJ, Lippard SJ. *Chem Rev*. 2013 DOI: 10.1021/cr4004314.
- [3]a). Dijt FJ, Fichtinger-Schepman AM, Berends F, Reedijk J. *Cancer Res*. 1988; 48:6058–6062. [PubMed: 3167856] b) Todd RC, Lippard SJ. *Metallomics*. 2009; 1:280–291. [PubMed: 20046924]
- [4]a). Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ, Judson IR. *J Inorg Biochem*. 1999; 77:111–115. [PubMed: 10626362] b) Hall MD, Mellor HR, Callaghan R, Hambley TW. *J Med Chem*. 2007; 50:3403–3411. [PubMed: 17602547]
- [5]. Pathak RK, Marrache S, Choi JH, Berding TB, Dhar S. *Angew Chem Int Ed Engl*. 2014; 53:1963–1967. [PubMed: 24453035]
- [6]. Kolb HC, Finn MG, Sharpless KB. *Angew Chem Int Ed Engl*. 2001; 40:2004–2021. [PubMed: 11433435]
- [7]. Zhang JZ, Bonnitich P, Wexselblatt E, Klein AV, Najajreh Y, Gibson D, Hambley TW. *Chem Eur J*. 2013; 19:1672–1676. [PubMed: 23255183]
- [8]a). Sletten EM, Bertozzi CR. *Angew Chem Int Ed Engl*. 2009; 48:6974–6998. [PubMed: 19714693] b) Sletten EM, Bertozzi CR. *Acc Chem Res*. 2011; 44:666–676. [PubMed: 21838330] c) Ledin PA, Kolishetti N, Boons G-J. *Macromolecules*. 2013; 46:7759–7768. [PubMed: 24511157]
- [9]a). Kuzmin A, Poloukhine A, Wolfert MA, Popik VV. *Bioconjug Chem*. 2010; 21:2076–2085. [PubMed: 20964340] b) Debets MF, van Berkel SS, Dommerholt J, Dirks AT, Rutjes FP, van Delft FL. *Acc Chem Res*. 2011; 44:805–815. [PubMed: 21766804] c) Koo H, Lee S, Na JH, Kim SH, Hahn SK, Choi K, Kwon IC, Jeong SY, Kim K. *Angew Chem Int Ed Engl*. 2012; 51:11836–11840. [PubMed: 23081905]
- [10]. Johnstone TC, Lippard SJ. *Inorg Chem*. 2013; 52:9915–9920. [PubMed: 23859129]
- [11]. Song Y, Suntharalingam K, Yeung JS, Royzen M, Lippard SJ. *Bioconjug Chem*. 2013; 24:1733–1740. [PubMed: 23957697]
- [12]a). Davis ME, Chen ZG, Shin DM. *Nat Rev Drug Discov*. 2008; 7:771–782. [PubMed: 18758474] b) Farokhzad OC. *Expert Opin Drug Deliv*. 2008; 5:927–929. [PubMed: 18754745] c) Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. *Chem Soc Rev*. 2012; 41:2971–3010. [PubMed: 22388185]
- [13]. Wheate NJ. *Nanomedicine*. 2012; 7:1285–1287. [PubMed: 22994954]
- [14]a). Langer R. *Nature*. 1998; 392:5–10. [PubMed: 9579855] b) Brannon-Peppas L, Blanchette JO. *Adv Drug Deliv Rev*. 2004; 56:1649–1659. [PubMed: 15350294]
- [15]a). Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. *J Control Rel*. 2001; 70:1–20. b) Langer R. *Science*. 2001; 293:58–59. [PubMed: 11441170] c) Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. *Proc Natl Acad Sci U S A*. 2011; 108:1850–1855. [PubMed: 21233423] d) Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. *Cancer Res*. 2004; 64:7668–7672. [PubMed: 15520166]
- [16]a). Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Hoven TV, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S. *Sci Transl Med*. 2012; 4:128ra139–128ra139. b) Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. *Clin Pharmacol Ther*. 2008; 83:761–769. [PubMed: 17957183] c) Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. *Nat Nanotechnol*. 2007; 2:751–760. [PubMed: 18654426]
- [17]a). Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. *Proc Natl Acad Sci U S A*. 2008; 105:17356–17361. [PubMed: 18978032] b) Graf N, Bielenberg DR, Kolishetti N, Muus C, Banyard J, Farokhzad OC, Lippard SJ. *ACS Nano*. 2012; 6:4530–4539. [PubMed: 22584163] c) Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, Langer R, Farokhzad OC. *Proc Natl Acad Sci U S A*. 2010; 107:17939–17944. [PubMed: 20921363]
- [18]. Marrache S, Dhar S. *Proc Natl Acad Sci U S A*. 2012; 109:16288–16293. [PubMed: 22991470]

- [19]a). Wexselblatt E, Gibson D. J Inorg Biochem. 2012; 117:220–229. [PubMed: 22877926] b)
Wexselblatt E, Yavin E, Gibson D. Angew Chem Int Ed Engl. 2013; 52:6059–6062. [PubMed:
23686723]
- [20]. Shi Y, Goodisman J, Dabrowiak JC. Inorg Chem. 2013; 52:9418–9426. [PubMed: 23889547]

Figure 1.

A SPAAC-based platform to Pt(IV) prodrugs from a single platinum precursor.

Figure 2.

(A) Cytotoxicity of Platin-Az, Platin-CLK, and cisplatin in PC3 and DU145 cells. (B) Installation of a Cy5.5 fluorescent reporter to Pt(IV) using Platin-Az and ADIBO-Cy5.5 using a single step SPAAC. (C) Live cell imaging of PC3 cells in presence of Platin-Cy5.5. Scale bar: 25 μm . DIC: differential interference contrast.

Figure 3. Size, zeta potential, loading, EE, and morphology of Platin-CLK-loaded PLGA-*b*-PEG-NPs and a comparison with Platin-Az loading in similar NPs.

Scheme 1.

Construction of precursors for SPAAC reaction and synthesis of Platin-CLK in a single step by click reaction.